Similarly, Liang et al. designed a dual-crosslinked hydrogel MN system based on dextran methacrylate (DexMA) and cyclodextrin–diamantane host–guest supramolecular (HGSM) for the synergistic delivery of the JAK inhibitor tofacitinib and the melanocyte-protective agent α-MSH to treat vitiligo [73] (Figure 9B). The gene discussed is STAMBP; the disease is vitiligo.